BIOVISION AG AND ABBOTT SIGN RESEARCH AGREEMENT

German biotech company BioVisioN AG signed an agreement with Abbott, a global, broad-based health care company, to collaborate on research relating to the discovery of novel biomarkers for lung cancer. According to the agreement, BioVisioN will analyze biological samples provided by Abbott to discover tumor biomarkers. Biomarkers play an important role in new strategies for the early diagnosis and effective treatment of diseases. Under the agreement, BioVisioN will receive research payments and, if successful, milestones and royalty payments.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1050639XSL_NEWSML_TO_NEWSML_WEB.xm)